Parp1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PARP1 (Poly(ADP-ribose) Polymerase 1) is a 113 kDa nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins. This post-translational modification, known as poly(ADP-ribos)ylation (PARylation), plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is the most abundant and well-characterized member of the PARP enzyme family.
PARP1 has a modular structure:
Crystal structures reveal the catalytic domain adopts an ADP-ribosyltransferase (ART) fold. The active site contains a conserved H-Y-E triplet motif (His-862, Tyr-896, Glu-988 in human PARP1) essential for catalysis.
In the nervous system, PARP1 functions include:
PARP1 overactivation contributes to dopaminergic neuron death through:
Therapeutic approaches: PARP inhibitors (PJ-34, DPQ) show neuroprotection in MPTP/6-OHDA models.
| Drug | Target | Status | Notes |
|---|---|---|---|
| PJ-34 | PARP1/2 | Preclinical | Neuroprotective in PD models |
| Olaparib | PARP1/2/3 | Approved (oncology) | Repurposing potential |
| Niraparib | PARP1/2 | Approved (oncology) | Brain-penetrant analogs in development |
| Rucaparib | PARP1/2/3 | Approved (oncology) | Being studied for neurodegeneration |
| Veliparib | PARP1/2 | Clinical trials | Poor brain penetration |
The study of Parp1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.